FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148909008> ?p ?o ?g. }

• W2148909008 endingPage "1474" @default.
• W2148909008 startingPage "1466" @default.
• W2148909008 abstract "To examine the cardiovascular effects of thiazolidinediones (TZDs), discuss concerns regarding this drug class and its relation to heart failure (HF) and myocardial infarction (MI), and address the clinical implications of HF and MI.Literature was accessed through MEDLINE (1979-April 2008) using the search terms type 2 diabetes mellitus, thiazolidinediones, cardiovascular events, heart failure, myocardial infarction, and edema. Reviews, meta-analyses, clinical trials, observational studies (case-control, cohort), and descriptive studies (case reports, case series) were included.All articles that were written in English and identified from the data sources were reviewed.The American Diabetes Association recommends metformin as first-line therapy for type 2 diabetes, with the subsequent addition of a TZD, sulfonylurea, or insulin if the target is not met. Beyond glucose lowering, TZDs improve various factors associated with cardiovascular risk. Whether the effects translate into beneficial cardiovascular outcomes is controversial. In PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events), pioglitazone did not produce a significant reduction in the primary endpoint that included a composite of coronary and vascular deaths, but the secondary composite endpoint of all-cause mortality, MI, or stroke was significantly reduced. Concerns related to HF have led to warnings in the labeling of TZDs. The drugs are contraindicated in patients with New York Heart Association Class III or IV HF. Rosiglitazone, but not pioglitazone, is associated with an increased risk of myocardial ischemic events, although the absolute magnitude is extremely small.Although the glycemic efficacy of TZDs is comparable to that of metformin, adverse effects and higher costs make TZDs less appealing for initial therapy. Among the TZDs, pioglitazone should be considered based on cardiovascular safety data. In combination with metformin, pioglitazone may be particularly beneficial for patients with diabetes and metabolic syndrome. For patients on rosiglitazone who are achieving glycemic goals and tolerating the therapy without apparent complications, rosiglitazone may be continued." @default.
• W2148909008 created "2016-06-24" @default.
• W2148909008 creator A5018561083 @default.
• W2148909008 creator A5049266332 @default.
• W2148909008 creator A5069732197 @default.
• W2148909008 date "2008-08-26" @default.
• W2148909008 modified "2023-10-03" @default.
• W2148909008 title "Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective" @default.
• W2148909008 cites W1969996708 @default.
• W2148909008 cites W1972136146 @default.
• W2148909008 cites W1973245422 @default.
• W2148909008 cites W1973852753 @default.
• W2148909008 cites W1977004017 @default.
• W2148909008 cites W1977188464 @default.
• W2148909008 cites W1977390060 @default.
• W2148909008 cites W1982311681 @default.
• W2148909008 cites W1982509198 @default.
• W2148909008 cites W1987941106 @default.
• W2148909008 cites W1990724339 @default.
• W2148909008 cites W1997416444 @default.
• W2148909008 cites W2001182083 @default.
• W2148909008 cites W2005888288 @default.
• W2148909008 cites W2007453649 @default.
• W2148909008 cites W2014759828 @default.
• W2148909008 cites W2025620168 @default.
• W2148909008 cites W2026229570 @default.
• W2148909008 cites W2034531911 @default.
• W2148909008 cites W2036169665 @default.
• W2148909008 cites W2049097098 @default.
• W2148909008 cites W2055218162 @default.
• W2148909008 cites W2055769770 @default.
• W2148909008 cites W2060060473 @default.
• W2148909008 cites W2064617441 @default.
• W2148909008 cites W2068402092 @default.
• W2148909008 cites W2072203364 @default.
• W2148909008 cites W2076076541 @default.
• W2148909008 cites W2077072698 @default.
• W2148909008 cites W2081276121 @default.
• W2148909008 cites W2085095809 @default.
• W2148909008 cites W2090260921 @default.
• W2148909008 cites W2100079513 @default.
• W2148909008 cites W2100407718 @default.
• W2148909008 cites W2102675827 @default.
• W2148909008 cites W2105719905 @default.
• W2148909008 cites W2110103927 @default.
• W2148909008 cites W2115607452 @default.
• W2148909008 cites W2118516040 @default.
• W2148909008 cites W2120936658 @default.
• W2148909008 cites W2127125241 @default.
• W2148909008 cites W2135378280 @default.
• W2148909008 cites W2135847267 @default.
• W2148909008 cites W2140857791 @default.
• W2148909008 cites W2143239235 @default.
• W2148909008 cites W2153449155 @default.
• W2148909008 cites W2154307369 @default.
• W2148909008 cites W2154572400 @default.
• W2148909008 cites W2157494695 @default.
• W2148909008 cites W2157738006 @default.
• W2148909008 cites W2159969745 @default.
• W2148909008 cites W2160362502 @default.
• W2148909008 cites W2161477191 @default.
• W2148909008 cites W2170952317 @default.
• W2148909008 cites W2171686316 @default.
• W2148909008 cites W2331274940 @default.
• W2148909008 cites W4240449862 @default.
• W2148909008 cites W4248661992 @default.
• W2148909008 cites W4252437054 @default.
• W2148909008 cites W71678318 @default.
• W2148909008 doi "https://doi.org/10.1345/aph.1k666" @default.
• W2148909008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18698014" @default.
• W2148909008 hasPublicationYear "2008" @default.
• W2148909008 type Work @default.
• W2148909008 sameAs 2148909008 @default.
• W2148909008 citedByCount "38" @default.
• W2148909008 countsByYear W21489090082012 @default.
• W2148909008 countsByYear W21489090082013 @default.
• W2148909008 countsByYear W21489090082014 @default.
• W2148909008 countsByYear W21489090082015 @default.
• W2148909008 countsByYear W21489090082017 @default.
• W2148909008 countsByYear W21489090082020 @default.
• W2148909008 crossrefType "journal-article" @default.
• W2148909008 hasAuthorship W2148909008A5018561083 @default.
• W2148909008 hasAuthorship W2148909008A5049266332 @default.
• W2148909008 hasAuthorship W2148909008A5069732197 @default.
• W2148909008 hasConcept C126322002 @default.
• W2148909008 hasConcept C127413603 @default.
• W2148909008 hasConcept C134018914 @default.
• W2148909008 hasConcept C164705383 @default.
• W2148909008 hasConcept C203092338 @default.
• W2148909008 hasConcept C2776923340 @default.
• W2148909008 hasConcept C2777180221 @default.
• W2148909008 hasConcept C2778198053 @default.
• W2148909008 hasConcept C2778384471 @default.
• W2148909008 hasConcept C2779306644 @default.
• W2148909008 hasConcept C2780152017 @default.
• W2148909008 hasConcept C2780323712 @default.
• W2148909008 hasConcept C2780473172 @default.
• W2148909008 hasConcept C2780645631 @default.

• next